More biosimilars have been marketed in Germany and Switzerland than in the United States, but uptake has increased over time in all countries, according to a study published online Dec. 2 in JAMA Network Open.
More biosimilars have been marketed in Germany and Switzerland than in the United States, but uptake has increased over time in all countries, according to a study published online Dec. 2 in JAMA Network Open.
